Tick‐borne encephalitis in patients vaccinated against this disease

Lotrič‐Furlan, Stanka; Bogovič, Petra; Avšič-Županc, Tatjana; Jelovšek, Mateja; Lusa, Lara; Strle, Franc

doi:10.1111/joim.12625

Cited by 57 publications

(63 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data on any failures in the field of vaccination are limited. According to published reports, a breakthrough disease after proper basic vaccination and/or timely boosters appears to be rare and tends to occur in higher age groups, but also in children (7,20).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of primary vaccination against tick-borne encephalitis in employees of the armed forces

Dorko

Bušová

Rimárová

et al. 2018

Cent Eur J Public Health

View full text Add to dashboard Cite

Objective: The aim of our study is to evaluate immune response after receiving the primary vaccination against tick-borne encephalitis (TBE), and to establish a link between seropositivity and selected factors in soldiers. Methods: Blood samples, questionnaires and vaccination records were obtained. TBE antibodies were detected using both ELISA and a neutralization test (NT). We used logistic regression for statistical analysis. Results: Overall, seropositivity (presence of IgG) was detected in 88% of participants. The proportion of seropositive subjects in relation to the number of doses of vaccine was 69% (2 doses) and 91% (3 doses). A statistically significant relationship was found between seropositivity and the number of vaccine doses. No statistical significance was identified in relation to age and sex. There was no statistical significance of seropositivity, depending on the time of the last dose of the vaccine. Conclusions: TBE immunisation should be targeted at individuals in the most affected locations and those at highest risk of exposure according to lifestyle and occupation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Active immunisation remains the most effective protective measure against TBE for people living in risk zones, those exposed at work and travelers to endemic areas (6,7).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of primary vaccination against tick-borne encephalitis in employees of the armed forces

Dorko

Bušová

Rimárová

et al. 2018

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…Similar to other immunizations, TBE vaccine protection does not reach the full 100% rate. A Swedish and a Slovenian series with clinical and serological evidence of TBE despite adequate immunization have been presented [26,27]. There is evidence that such breakthroughs occur mainly in adults, particularly in older age.…”

Section: Vaccinationmentioning

confidence: 99%

Tick-borne Encephalitis—Need to know for Professionals outside Endemic Areas

Steffen¹

2019

DSAHMJ

View full text Add to dashboard Cite

Tick-borne Encephalitis (TBE) is an arboviral infection widespread in Europe and northern parts of Asia. Ticks transmit the associated flavivirus usually between March and November to people with outdoor activities in the countryside, in gardens or, rarely, in urban parks. The clinical picture of TBE has two phases: after an uncharacteristic febrile illness and a brief interval in which neurological symptoms occur in a minority of the infected patients. In children, meningitis is the predominant syndrome, whereas the proportion of patients with more severe encephalitis and encephalomyelitis increases with growing age. Consequently, children may suffer from cognitive defects and adults from neurological defects after the acute phase. As there is no therapy for TBE, prevention is of paramount importance. The first line of defense is to avoid tick "bites" (actually stings). Various effective and well-tolerated vaccines are marketed in Europe, all parts of Russia, and in China.

show abstract

“…In Sweden, the number of notified cases is increasing and reached a record-high in 2017 (391 cases), with almost the same level in 2018 (385 cases) ( Figure 1) [4]. Effective vaccines are available, but vaccine failures occur [5,6]. The number of sold vaccine doses has also increased during the same period and reached 1.2 million doses in 2018, which is double the amount sold the years before ( Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Antibody responses to tick-borne encephalitis virus non-structural protein 1 and whole virus antigen–a new tool in the assessment of suspected vaccine failure patients

Albinsson

Rönnberg

Vene

et al. 2019

Infection Ecology & Epidemiology

View full text Add to dashboard Cite

We report a new tool for improved serological diagnostics in suspected tick-borne encephalitis (TBE) vaccine failure cases. Due to an increase in the incidence of disease as well as the number of vaccinees, specific and simplified diagnostic methods are needed. Antibody responses to TBE-virus (TBEV) non-structural protein 1 (NS1) are detectable post TBEV infection but not post vaccination. We have used samples from 14 previously confirmed Swedish TBEV vaccine failure patients to study antibody responses against NS1 and whole virus antigens, respectively. Our conclusion is that the detection of antibodies directed to TBEV NS1 antigen is a useful tool to considerably simplify and improve the quality in investigations regarding suspected TBEV infection in vaccinated patients.

show abstract

Tick‐borne encephalitis in patients vaccinated against this disease

Cited by 57 publications

References 31 publications

Effectiveness of primary vaccination against tick-borne encephalitis in employees of the armed forces

Effectiveness of primary vaccination against tick-borne encephalitis in employees of the armed forces

Tick-borne Encephalitis—Need to know for Professionals outside Endemic Areas

Antibody responses to tick-borne encephalitis virus non-structural protein 1 and whole virus antigen–a new tool in the assessment of suspected vaccine failure patients

Contact Info

Product

Resources

About